Utility of 68Ga-PSMA-11 PET/CT in Imaging of Glioma—A Pilot Study
Tóm tắt
Imaging of gliomas remains challenging. The aim of the study was to assess the feasibility of using 68Ga-PSMA-11 PET/CT for imaging gliomas.
Fifteen patients with glioma from 2 centers were included in the study. Ten patients were treated cases of glioblastoma with suspected recurrence. Two patients were sent for assessing the nature (primary lesion/metastasis) of space-occupying lesion in the brain; 3 patients were imaged immediately after surgery and before radiotherapy. Target-to-background ratios (TBR) for the brain lesions were calculated using contralateral cerebellar uptake as background.
Among the 10 cases with suspected recurrence, scan was positive in 9, subsequent surgery was done, and histopathology proved it to be true recurrence. In the scan-negative case on follow-up, no evidence of disease could be made clinically or radiologically. Among the other cases the presence or absence of disease could be unequivocally identified on the 68Ga-PSMA-11 brain scan and correlated with the histopathology or other imaging. Apart from the visual assessment quantitative assessment of the lesions with TBR also showed a significantly high TBR value for those with true disease compared with those with no disease.
In the evaluation of gliomas, 68Ga-PSMA-11 PET/CT brain imaging is a potentially useful imaging tool. The use of 68Ga-PSMA-11 brain PET/CT in evaluation of recurrent glioma seems promising. Absence of physiological uptake of 68Ga-PSMA-11 in the normal brain parenchyma results in high TBR values and consequently better visualization of glioma lesions.
Từ khóa
Tài liệu tham khảo
1997, Prostate-specific membrane antigen expression in normal and malignant human tissues, Clin Cancer Res, 3, 81
1998, Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen, Cancer, 83, 2259, 10.1002/(SICI)1097-0142(19981201)83:11<2259::AID-CNCR5>3.0.CO;2-T
2004, Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer, J Cell Biochem, 91, 528, 10.1002/jcb.10661
2012, 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging, Bioconjug Chem, 23, 688, 10.1021/bc200279b
2015, The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 42, 197, 10.1007/s00259-014-2949-6
2015, Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy, J Nucl Med, 56, 668, 10.2967/jnumed.115.154153
2016, 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT, Clin Nucl Med, 41, 515, 10.1097/RLU.0000000000001197
2016, Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer, Eur J Nucl Med Mol Imaging, 43, 1400, 10.1007/s00259-016-3346-0
2016, (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients, Eur J Nucl Med Mol Imaging, 43, 34, 10.1007/s00259-015-3188-1
2017, 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0, Eur J Nucl Med Mol Imaging, 44, 1014, 10.1007/s00259-017-3670-z
2014, (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma, Eur J Nucl Med Mol Imaging, 41, 1461, 10.1007/s00259-014-2766-y
2016, (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma, Eur J Nucl Med Mol Imaging, 43, 795, 10.1007/s00259-015-3297-x
2016, PSMA expression in papillary thyroid carcinoma: opening a new horizon in management of thyroid cancer?, Clin Nucl Med, 41, e263, 10.1097/RLU.0000000000001148
2016, Elevated 68Ga prostate-specific membrane antigen activity in metastatic non-small cell lung cancer, Clin Nucl Med, 41, 414, 10.1097/RLU.0000000000001139
2016, Follicular lymphoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT, Clin Nucl Med, 41, 500, 10.1097/RLU.0000000000001169
2017, 68Ga-PSMA uptake in an incidentally detected gastrointestinal stromal tumor in a case of suspected carcinoma prostate, Clin Nucl Med, 42, e447, 10.1097/RLU.0000000000001774
1999, Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature, Cancer Res, 59, 3192
1999, Prostate-specific membrane antigen is produced in tumor-associated neovasculature, Clin Cancer Res, 5, 2674
2014, Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases, Cancer Cell Int, 14, 26, 10.1186/1475-2867-14-26
2017, Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors-preliminary analysis, Clin Nucl Med, 42, e41, 10.1097/RLU.0000000000001451
2016, Preparation of [(68)Ga]PSMA-11 for PET-CT imaging using a manual synthesis module and organic matrix based (68)Ge/(68)Ga generator, Nucl Med Biol, 43, 463, 10.1016/j.nucmedbio.2016.05.006
2006, Epidemiology and molecular pathology of glioma, Nat Clin Pract Neurol, 2, 494, 10.1038/ncpneuro0289
2012, F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI, Eur J Radiol, 81, 508, 10.1016/j.ejrad.2011.01.080
2010, Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences, Nucl Med Biol, 37, 727, 10.1016/j.nucmedbio.2010.04.185
2012, Gallium-68: a new trend in PET radiopharmacy, Curr Radiopharm, 5, 142, 10.2174/1874471011205020142
2014, (68)Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study, Mol Pharm, 11, 3923, 10.1021/mp5003224
2015, Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy?, PLoS One, 10, e0122269, 10.1371/journal.pone.0122269
2011, Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme, Arch Pathol Lab Med, 135, 1486, 10.5858/arpa.2010-0740-OA
2015, In vivo visualization of prostate-specific membrane antigen in glioblastoma, Eur J Nucl Med Mol Imaging, 42, 170, 10.1007/s00259-014-2921-5
2017, Prostate-specific membrane antigen-targeted imaging with [18F]DCFPyL in high-grade gliomas, Clin Nucl Med, 42, e433, 10.1097/RLU.0000000000001769
2018, Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody, J Neurooncol